Retrospective, monocentric observational study of pregnant women with an increased vascular risk and a primary prophylactic anticoagulation with certoparin in an intermediate dose of 8000iU sc od.

• Conditions: I80; O15; Phlebitis and thrombophlebitis; Eclampsia

• Registration Number: DRKS00018099
• Lead Sponsor: Klinikum Heidenheim Medizinische Klinik I

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-09-04
• Study Completion: 2019-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 74

Inclusion Criteria

Pregnancy with moderate or high vascular risk; consent to off-label use of Certoparin

Exclusion Criteria

Pregnancy with low or very high vascular risk; contraindication to the administration of Certoparin

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of primary prophylactic anticoagulation with certoparin at a weight-independent dose of 8000 iE once daily; vascular endpoints such as thromboembolism and eclampsia are assessed

Secondary Outcome Measures

Name	Time	Method
Safety of primary prophylactic anticoagulation with certoparin in a weight-independent dose of 8000 iE once daily; the rate of bleeding complications, skeletal complications and birth complications as well as the newborn's status (height, weight, limitations) are measured.